Bloomberg:IMMNOV@SS

Immunovia appoints Dr. Lisa Ford as Clinical Laboratory Director

Retrieved on:

星期一, 四月 29, 2024

University, Lab, Pancreatic cancer, Survival, Communication, Clinical Laboratory, Research, Duke University

LUND, Sweden, April 29, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces the appointment of Dr. Lisa Ford as Clinical Laboratory Director.

Key Points:

LUND, Sweden, April 29, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces the appointment of Dr. Lisa Ford as Clinical Laboratory Director.
As Clinical Laboratory Director, Dr. Ford will lead lab operations as well as research and development of Immunovia's next-generation test.
Lisa brings over twenty years of experience leading laboratory project teams through research, development, validation (clinical and analytical) and implementation of diagnostic tests.
from University of California in Chemistry, and board certification as a high-complexity clinical laboratory director from the American Board of Bioanalysis.

Immunovia streamlines lab operations with move to Research Triangle Park, North Carolina

Retrieved on:

星期一, 四月 29, 2024

Survival, Research Triangle Park, Triangle Park (Quezon City), RTP, Pancreatic cancer

This work will be conducted at the lab in Research Triangle Park under the leadership and direction of Dr. Lisa Ford.

Key Points:

This work will be conducted at the lab in Research Triangle Park under the leadership and direction of Dr. Lisa Ford.
Moving its lab and U.S. headquarters to Research Triangle Park supports the strategy Immunovia announced in July 2023 to streamline operations and reduce costs.
The new space in Research Triangle Park (RTP) will be significantly smaller and less expensive than the company's existing lab in Marlborough, Massachusetts.
The lower cost of labor in Research Triangle Park should enable the company to staff the new lab at a lower cost.

Immunovia appoints Dr. Lisa Ford as Clinical Laboratory Director

Retrieved on:

星期一, 四月 29, 2024

University, Lab, Pancreatic cancer, Survival, Communication, Clinical Laboratory, Research, Duke University

LUND, Sweden, April 29, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces the appointment of Dr. Lisa Ford as Clinical Laboratory Director.

Key Points:

LUND, Sweden, April 29, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces the appointment of Dr. Lisa Ford as Clinical Laboratory Director.
As Clinical Laboratory Director, Dr. Ford will lead lab operations as well as research and development of Immunovia's next-generation test.
Lisa brings over twenty years of experience leading laboratory project teams through research, development, validation (clinical and analytical) and implementation of diagnostic tests.
from University of California in Chemistry, and board certification as a high-complexity clinical laboratory director from the American Board of Bioanalysis.

Immunovia streamlines lab operations with move to Research Triangle Park, North Carolina

Retrieved on:

星期一, 四月 29, 2024

Survival, Research Triangle Park, Triangle Park (Quezon City), RTP, Pancreatic cancer

This work will be conducted at the lab in Research Triangle Park under the leadership and direction of Dr. Lisa Ford.

Key Points:

This work will be conducted at the lab in Research Triangle Park under the leadership and direction of Dr. Lisa Ford.
Moving its lab and U.S. headquarters to Research Triangle Park supports the strategy Immunovia announced in July 2023 to streamline operations and reduce costs.
The new space in Research Triangle Park (RTP) will be significantly smaller and less expensive than the company's existing lab in Marlborough, Massachusetts.
The lower cost of labor in Research Triangle Park should enable the company to staff the new lab at a lower cost.

Invitation to Immunovia's Q1 presentation

Retrieved on:

星期二, 四月 23, 2024

Webcast, CFO, Telephone, Q&A

Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET.

Key Points:

Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET.
The report together with the presentation slides will be available at www.immunovia.com
Jeff Borcherding, CEO and President, and Karin Almqvist Liwendahl, CFO, will present on Immunovia's development.
The presentation will be held in English and be followed by a Q&A session.
A recording of the presentation will be available on Immunovia's website.

Invitation to Immunovia's Q1 presentation

Retrieved on:

星期二, 四月 23, 2024

Webcast, CFO, Telephone, Q&A

Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET.

Key Points:

Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET.
The report together with the presentation slides will be available at www.immunovia.com
Jeff Borcherding, CEO and President, and Karin Almqvist Liwendahl, CFO, will present on Immunovia's development.
The presentation will be held in English and be followed by a Q&A session.
A recording of the presentation will be available on Immunovia's website.

Immunovia announces updated financial calendar

Retrieved on:

星期一, 四月 22, 2024

Nasdaq Stockholm, Antibody, Patient, Protein, Risk, Pancreatic cancer, Pharmaceutical industry

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection.

Key Points:

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection.
Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia announces updated financial calendar

Retrieved on:

星期一, 四月 22, 2024

Nasdaq Stockholm, Antibody, Patient, Protein, Risk, Pancreatic cancer, Pharmaceutical industry

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection.

Key Points:

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection.
Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test

Retrieved on:

星期一, 四月 22, 2024

Cancer, Risk, Pancreatic cancer, ELISA, Survival, EUS, Heredity, PDAC, Patient, MRI, Magnetic resonance imaging, CA19-9, Biomarker, Medical imaging

The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.

Key Points:

The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.
Importantly, these results confirm the technical advancement of the next-generation test over Immunovia's first-generation test, IMMray PanCan-d.
Furthermore, the new test does not provide indeterminate or "borderline" results; all patients are classified as positive or negative for pancreatic cancer.
People at risk for pancreatic cancer need a simple, fast, and easy blood test to detect cancer early.

Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test

Retrieved on:

星期一, 四月 22, 2024

Cancer, Risk, Pancreatic cancer, ELISA, Survival, EUS, Heredity, PDAC, Patient, MRI, Magnetic resonance imaging, CA19-9, Biomarker, Medical imaging

The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.

Key Points:

The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.
Importantly, these results confirm the technical advancement of the next-generation test over Immunovia's first-generation test, IMMray PanCan-d.
Furthermore, the new test does not provide indeterminate or "borderline" results; all patients are classified as positive or negative for pancreatic cancer.
People at risk for pancreatic cancer need a simple, fast, and easy blood test to detect cancer early.